Charles Schwab Investment Management Inc Cassava Sciences Inc Transaction History

Charles Schwab Investment Management Inc

$557 Billion
Q2 2025

A detailed history of Charles Schwab Investment Management Inc transactions in Cassava Sciences Inc stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 265,290 shares of SAVA stock, worth $615,472. This represents 0.0% of its overall portfolio holdings.

Number of Shares

265,290

Previous 361,253 26.56%

Holding current value

$615,472

Previous $541,000 11.28%

% of portfolio

0.0%

Previous 0.0%

21 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 12, 2025	SELL	$1.19 - $2.24 $114,195 - $214,957	-95,963 Reduced 26.56%	265,290 $480,000
Q1 2025 May 09, 2025	BUY	$1.5 - $3.02 $62,266 - $125,363	41,511 Added 12.98%	361,253 $541,000
Q4 2024 Feb 06, 2025	SELL	$2.29 - $32.18 $96,305 - $1.35 Million	-42,055 Reduced 11.62%	319,742 $754,000
Q3 2024 Nov 12, 2024	BUY	$9.57 - $35.08 $99,805 - $365,849	10,429 Added 2.97%	361,797 $10.6 Million
Q2 2024 Aug 12, 2024	BUY	$12.35 - $26.11 $431,965 - $913,249	34,977 Added 11.05%	351,368 $4.34 Million
Q1 2024 May 08, 2024	BUY	$18.44 - $26.41 $139,314 - $199,527	7,555 Added 2.45%	316,391 $6.42 Million
Q4 2023 Feb 06, 2024	BUY	$12.64 - $30.11 $52,013 - $123,902	4,115 Added 1.35%	308,836 $6.95 Million
Q3 2023 Nov 08, 2023	BUY	$16.64 - $25.32 $154,984 - $235,830	9,314 Added 3.15%	304,721 $5.07 Million
Q2 2023 Aug 09, 2023	BUY	$21.59 - $27.88 $99,119 - $127,997	4,591 Added 1.58%	295,407 $7.24 Million
Q1 2023 May 11, 2023	BUY	$23.46 - $36.44 $251,139 - $390,090	10,705 Added 3.82%	290,816 $7.01 Million
Q4 2022 Feb 13, 2023	BUY	$27.82 - $44.16 $143,912 - $228,439	5,173 Added 1.88%	280,111 $8.27 Million
Q3 2022 Nov 14, 2022	BUY	$16.33 - $51.06 $119,649 - $374,116	7,327 Added 2.74%	274,938 $11.5 Million
Q2 2022 Aug 15, 2022	SELL	$17.22 - $38.47 $109,364 - $244,322	-6,351 Reduced 2.32%	267,611 $7.53 Million
Q1 2022 May 13, 2022	BUY	$32.6 - $53.05 $210,661 - $342,809	6,462 Added 2.42%	273,962 $10.2 Million
Q4 2021 Feb 11, 2022	BUY	$36.77 - $90.91 $191,534 - $473,550	5,209 Added 1.99%	267,500 $11.7 Million
Q3 2021 Nov 16, 2021	BUY	$41.79 - $135.3 $6.99 Million - $22.6 Million	167,214 Added 175.87%	262,291 $16.3 Million
Q2 2021 Aug 16, 2021	BUY	$32.15 - $89.72 $387,118 - $1.08 Million	12,041 Added 14.5%	95,077 $8.12 Million
Q1 2021 May 17, 2021	BUY	$7.09 - $87.95 $41,497 - $514,771	5,853 Added 7.58%	83,036 $3.73 Million
Q4 2020 Feb 16, 2021	BUY	$6.79 - $12.25 $137,470 - $248,013	20,246 Added 35.56%	77,183 $527,000
Q3 2020 Nov 13, 2020	BUY	$2.86 - $11.51 $20,020 - $80,570	7,000 Added 14.02%	56,937 $656,000
Q2 2020 Aug 14, 2020	BUY	$2.04 - $9.64 $101,871 - $481,392	49,937 New	49,937 $154,000

Others Institutions Holding SAVA

# of Institutions

131

Shares Held

14.2M

Call Options Held

962K

Put Options Held

864K

View Full List

About CASSAVA SCIENCES INC

Ticker SAVA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,097,900
Market Cap $93M
Description
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's...

More about SAVA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Charles Schwab Investment Management Inc with notifications on news.

Account

Charles Schwab Investment Management Inc Cassava Sciences Inc Transaction History